Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Melissa Alsina, Rafael Fonseca, Edward F. Wilson, A. Nelida Belle, Elvira Gerbino, Tammy Price-Troska, Rose M. Overton, Gregory Ahmann, Laura M. Bruzek, Alex A. Adjei, Scott H. Kaufmann, John J. Wright, Daniel Sullivan, Benjamin Djulbegovic, Alan B. Cantor, Philip R. Greipp, William S. Dalton, Saïd M. Sebti
Dive into the research topics of 'Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma'. Together they form a unique fingerprint.